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Résumé en
anglais
Scedosporium apiospermum is a soil fungus which can cause severe and often fatal
cerebral infections in both immunocompetent patients in the event of near drowning
and immunosuppressed patients such as lung transplant recipients. Because of the
low susceptibility of this fungus to antifungal drugs, and the low permeability of the
blood-brain barrier (BBB), therapeutic drug monitoring is necessary to reach an
effective tissue concentration with limited side effects. Indeed, diffusion of the drug
in the brain is dependent on several parameters, such as the integrity of the BBB
and the activity of efflux pumps. To evaluate drug diffusion, two experimental
models were developed in immunocompetent and immunosuppressed rats. Inocula
were administered via the penile vein and a clinical scale (0-9) was established,
based on weight and clinical and neurologic signs evaluated by the tail suspension
test. Cerebral involvement was confirmed by magnetic resonance imaging and
histologic examination of brain sections after hematoxylin-eosin-safran or silver
staining. Voriconazole or posaconazole was given to the rats at doses ranging from
10 to 75 mg/kg/day via i.v. or oral routes, respectively. Whatever the immune status,
the effective doses (defined by a doubling of the survival time and the absence of
neurologic sequelae) were 30 mg/kg/day for voriconazole and 50 mg/kg/day for
posaconazole. Overall, the results demonstrated that these models may constitute
valuable tools for the performance of pharmacokinetic and pharmacodynamic
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